Advertisement
Advertisement
U.S. markets close in 59 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Organovo Holdings, Inc. (ONVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.2000-0.0200 (-1.64%)
As of 02:16PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close1.2200
Open1.2100
Bid1.1900 x 900
Ask1.2000 x 800
Day's Range1.1801 - 1.2299
52 Week Range1.0000 - 3.4000
Volume10,789
Avg. Volume39,147
Market Cap10.462M
Beta (5Y Monthly)0.88
PE Ratio (TTM)N/A
EPS (TTM)-2.0100
Earnings DateNov 08, 2023 - Nov 12, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ONVO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Organovo Holdings, Inc.
    ARWR: Lowering target price to $28.00ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $28.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Organovo to Participate in the H.C. Wainwright Global Investment Conference

    SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in three-dimensional (3D) human tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Founder and Executive Chairman, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Co

  • GuruFocus.com

    Is Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap

    Unpacking the Financial Health of Organovo Holdings Inc (ONVO) to Determine Its Investment Viability

  • GlobeNewswire

    Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

    SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease, today announced more details about its clinical program for FXR314, an FXR agonist that has completed initial clinical trials. FXR314 is a drug with safety and tolerability after daily oral

Advertisement
Advertisement